secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuphoria Therapeutics Inc. (NEUP)
CIK:        0001191070
Form:       8-K
Filed at:   2024-10-02T23:59:59+00:00
Accession:  0001213900-24-084175
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionomics to re-domicile from Australia to US via scheme of arrangement with Neuphoria
--------------------------------------------------------------------------------

- Holders receive 1 Neuphoria share per 1,440 ordinary shares or per 8 ADSs; estimated post-domicile Nasdaq price ~$3.50.
- Board unanimously recommends approval; shareholder vote expected late Nov 2024, implementation early Dec 2024.
- Re-domicile driven by loss of foreign private issuer status, reduced compliance costs, and greater US investor access.
- No material change to assets, management, operations, or strategy expected; structure designed to be tax-neutral.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1191070/000121390024084175/0001213900-24-084175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1191070/000121390024084175/ea0216237-8k_bionomic.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-084175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer